Skip to main content
Erschienen in: Journal of Clinical Immunology 2/2019

22.01.2019 | Original Article

Neurological Involvement in Childhood Evans Syndrome

verfasst von: Thomas Pincez, Bénédicte Neven, Hubert Ducou Le Pointe, Pascale Varlet, Helder Fernandes, Albane Gareton, Guy Leverger, Thierry Leblanc, Hervé Chambost, Gérard Michel, Marlène Pasquet, Frédéric Millot, Olivier Hermine, Alexis Mathian, Marie Hully, Hélène Zephir, Mohamed Hamidou, Jean-Marc Durand, Yves Perel, Judith Landman-Parker, Fréderic Rieux-Laucat, Nathalie Aladjidi

Erschienen in: Journal of Clinical Immunology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA) are associated in the definition of Evans syndrome (ES). The occurrence of neurological involvement in this population is poorly described and suggests an underlying primary immunodeficiency (PID). We aimed to describe the clinical manifestations, evolution, and PID profiles of these patients.

Methods

OBS’CEREVANCE is a French, nationwide prospective cohort that includes children with chronic ITP, AIHA, and ES. Patients with a neurological involvement were described. Centralized radiological and pathological reviews and genetic analyses were performed.

Results

On October 2016, eight patients (7/181 ES, 1/371 AIHA, and 0/615 ITP) were identified, all male, with a median age (range) at cytopenia onset of 11.5 years (1.6–15.8). Neurological symptoms appeared with a median delay of 6 years (2.5–18) after cytopenia and were polymorphic: seizures (n = 4), cranial nerve palsy (n = 2), Brown-Sequard syndrome (n = 2), intracranial pressure (n = 2), vertigo (n = 1), and/or sensory neuropathy (n = 1). Magnetic resonance imaging (MRI) showed inflammatory lesions, confirmed by pathology for five patients with macrophagic or lymphoplasmocytic infiltrates. All patients had other relevant immunopathological manifestations: pulmonary nodules (n = 6), lymphoproliferation (n = 4), abnormal immunophenotype (n = 8), and hypogammaglobulinemia (n = 7). Treatment consisted of steroids that improved symptomatology and MRI. Five patients relapsed and three had an asymptomatic radiological progression. A PID was identified in 3/8 patients: 22q11.2 microdeletion (n = 1) and CTLA deficiency (n = 2).

Conclusion

Neurological involvement is a rare and severe late event in the course of childhood ES, which can reveal an underlying PID. Imaging and pathology examination highlight a causative immune dysregulation that may guide targeted therapeutic strategies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–80.PubMed Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–80.PubMed
2.
Zurück zum Zitat Moulis G, Palmaro A, Montastruc J-L, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–15.CrossRefPubMed Moulis G, Palmaro A, Montastruc J-L, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–15.CrossRefPubMed
3.
Zurück zum Zitat Aladjidi N, Fernandes H, Leblanc T, Vareliette A, Rieux-Laucat F, Bertrand Y, et al. Evans syndrome in children: long-term outcome in a prospective French national observational cohort. Front Pediatr. 2015;3:79.CrossRefPubMedPubMedCentral Aladjidi N, Fernandes H, Leblanc T, Vareliette A, Rieux-Laucat F, Bertrand Y, et al. Evans syndrome in children: long-term outcome in a prospective French national observational cohort. Front Pediatr. 2015;3:79.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Aladjidi N, Jutand M-A, Beaubois C, Fernandes H, Jeanpetit J, Coureau G, et al. Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatr Blood Cancer. 2017; 64(12). Aladjidi N, Jutand M-A, Beaubois C, Fernandes H, Jeanpetit J, Coureau G, et al. Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatr Blood Cancer. 2017; 64(12).
5.
Zurück zum Zitat Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010;115(11):2142–5.CrossRefPubMed Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010;115(11):2142–5.CrossRefPubMed
6.
Zurück zum Zitat Zuelzer WW, Mastrangelo R, Stulberg CS, Poulik MD, Page RH, Thompson RI. Autoimmune hemolytic anemia. Natural history and viral-immunologic interactions in childhood. Am J Med. 1970;49(1):80–93.CrossRefPubMed Zuelzer WW, Mastrangelo R, Stulberg CS, Poulik MD, Page RH, Thompson RI. Autoimmune hemolytic anemia. Natural history and viral-immunologic interactions in childhood. Am J Med. 1970;49(1):80–93.CrossRefPubMed
7.
Zurück zum Zitat Savaşan S, Warrier I, Buck S, Kaplan J, Ravindranath Y. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans’ syndrome. Clin Immunol. 2007;125(3):224–9.CrossRefPubMed Savaşan S, Warrier I, Buck S, Kaplan J, Ravindranath Y. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans’ syndrome. Clin Immunol. 2007;125(3):224–9.CrossRefPubMed
8.
Zurück zum Zitat Michel M, Chanet V, Galicier L, Ruivard M, Levy Y, Hermine O, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore). 2004;83(4):254–63.CrossRef Michel M, Chanet V, Galicier L, Ruivard M, Levy Y, Hermine O, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore). 2004;83(4):254–63.CrossRef
9.
Zurück zum Zitat Heeney MM, Zimmerman SA, Ware RE. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr. 2003;143(5):662–5.CrossRefPubMed Heeney MM, Zimmerman SA, Ware RE. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr. 2003;143(5):662–5.CrossRefPubMed
10.
Zurück zum Zitat Fischer A, Provot J, Jais J-P, Alcais A, Mahlaoui N. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017;140(5):1388–1393.e8.CrossRefPubMed Fischer A, Provot J, Jais J-P, Alcais A, Mahlaoui N. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017;140(5):1388–1393.e8.CrossRefPubMed
11.
Zurück zum Zitat Parvaneh N, Casanova J-L, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol. 2013;131(2):314–23.CrossRefPubMed Parvaneh N, Casanova J-L, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol. 2013;131(2):314–23.CrossRefPubMed
12.
Zurück zum Zitat Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood. 2014;124(15):2337–44.CrossRefPubMedPubMedCentral Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood. 2014;124(15):2337–44.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Bousfiha A, Jeddane L, Picard C, Ailal F, Gaspar HB, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.CrossRefPubMed Bousfiha A, Jeddane L, Picard C, Ailal F, Gaspar HB, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.CrossRefPubMed
14.
Zurück zum Zitat Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood. 2016;128(8):1037–42.CrossRefPubMedPubMedCentral Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood. 2016;128(8):1037–42.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Elgizouli M, Lowe DM, Speckmann C, Schubert D, Hülsdünker J, Eskandarian Z, et al. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol. 2016;183(2):221–9.CrossRefPubMed Elgizouli M, Lowe DM, Speckmann C, Schubert D, Hülsdünker J, Eskandarian Z, et al. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol. 2016;183(2):221–9.CrossRefPubMed
16.
Zurück zum Zitat Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011 May 1;96(5):655–63.CrossRefPubMedPubMedCentral Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011 May 1;96(5):655–63.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. 2002;141(5):683–8.CrossRefPubMed Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. 2002;141(5):683–8.CrossRefPubMed
18.
Zurück zum Zitat Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers E-J, Berk R, et al. Redefine statistical significance. Nat Hum Behav. 2018;2(1):6–10.CrossRefPubMed Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers E-J, Berk R, et al. Redefine statistical significance. Nat Hum Behav. 2018;2(1):6–10.CrossRefPubMed
19.
Zurück zum Zitat Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol. 2010;134(2):97–103.CrossRefPubMed Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol. 2010;134(2):97–103.CrossRefPubMed
20.
Zurück zum Zitat Simon OJ, Kuhlmann T, Bittner S, Müller-Tidow C, Weigt J, Wiendl H, et al. Evans syndrome associated with sterile inflammation of the central nervous system: a case report. J Med Case Rep. 2013;7:262.CrossRefPubMedPubMedCentral Simon OJ, Kuhlmann T, Bittner S, Müller-Tidow C, Weigt J, Wiendl H, et al. Evans syndrome associated with sterile inflammation of the central nervous system: a case report. J Med Case Rep. 2013;7:262.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Stübgen J-P. Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura. J Neurol Sci. 2010;288(1–2):178–81.CrossRefPubMed Stübgen J-P. Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura. J Neurol Sci. 2010;288(1–2):178–81.CrossRefPubMed
22.
Zurück zum Zitat Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, et al. Multiple sclerosis following splenectomy as a treatment for idiopathic thrombocytopenic purpura. Intern Med Tokyo Jpn. 2005;44(7):747–9.CrossRef Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, et al. Multiple sclerosis following splenectomy as a treatment for idiopathic thrombocytopenic purpura. Intern Med Tokyo Jpn. 2005;44(7):747–9.CrossRef
23.
Zurück zum Zitat Mizuno H, Sato S, Ohnishi Y, Takahashi T, Nakashima I, Fujihara K, et al. A case of myelitis with anti-aquaporin 4 antibody concomitant with immune thrombocytopenic purpura. Rinshō Shinkeigaku Clin Neurol. 2014;54(3):195–9.CrossRef Mizuno H, Sato S, Ohnishi Y, Takahashi T, Nakashima I, Fujihara K, et al. A case of myelitis with anti-aquaporin 4 antibody concomitant with immune thrombocytopenic purpura. Rinshō Shinkeigaku Clin Neurol. 2014;54(3):195–9.CrossRef
24.
Zurück zum Zitat Guez T, Smadja D, Mas JL, Sicard D. Chronic inflammatory demyelinating polyradiculoneuropathy associated with Evans’ syndrome. Eur J Med. 1992;1(6):374–6.PubMed Guez T, Smadja D, Mas JL, Sicard D. Chronic inflammatory demyelinating polyradiculoneuropathy associated with Evans’ syndrome. Eur J Med. 1992;1(6):374–6.PubMed
25.
Zurück zum Zitat Knecht H, Baumberger M, Tobòn A, Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology. 2004;63(4):730–2.CrossRefPubMed Knecht H, Baumberger M, Tobòn A, Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology. 2004;63(4):730–2.CrossRefPubMed
27.
Zurück zum Zitat Sipurzynski J, Fahrner B, Kerbl R, Crazzolara R, Jones N, Ebetsberger G, et al. Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients. Semin Hematol. 2016;53(Suppl 1):S43–7.CrossRefPubMed Sipurzynski J, Fahrner B, Kerbl R, Crazzolara R, Jones N, Ebetsberger G, et al. Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients. Semin Hematol. 2016;53(Suppl 1):S43–7.CrossRefPubMed
28.
Zurück zum Zitat Miano M, Scalzone M, Perri K, Palmisani E, Caviglia I, Micalizzi C, et al. Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune Cytopenias: a single Centre experience. Br J Haematol. 2015;171(2):247–53.CrossRefPubMed Miano M, Scalzone M, Perri K, Palmisani E, Caviglia I, Micalizzi C, et al. Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune Cytopenias: a single Centre experience. Br J Haematol. 2015;171(2):247–53.CrossRefPubMed
29.
Zurück zum Zitat Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17–28. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17–28.
30.
Zurück zum Zitat Miano M, Ramenghi U, Russo G, Rubert L, Barone A, Tucci F, et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol. 2016;175(3):490–5.CrossRefPubMed Miano M, Ramenghi U, Russo G, Rubert L, Barone A, Tucci F, et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol. 2016;175(3):490–5.CrossRefPubMed
31.
Zurück zum Zitat Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of immune thrombocytopenia (itp) and Evans syndrome (es): a single institution’s experience. J Pediatr Hematol Oncol. 2017;39(6):420–4.CrossRefPubMed Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of immune thrombocytopenia (itp) and Evans syndrome (es): a single institution’s experience. J Pediatr Hematol Oncol. 2017;39(6):420–4.CrossRefPubMed
32.
Zurück zum Zitat Androdias G, Maillet D, Marignier R, Pinède L, Confavreux C, Broussolle C, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–72.CrossRefPubMed Androdias G, Maillet D, Marignier R, Pinède L, Confavreux C, Broussolle C, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–72.CrossRefPubMed
33.
Zurück zum Zitat Garssen MPJ, van Koningsveld R, van Doorn PA, Merkies ISJ, Scheltens-de Boer M, van Leusden JA, et al. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry. 2007;78(9):1012–3.CrossRefPubMedPubMedCentral Garssen MPJ, van Koningsveld R, van Doorn PA, Merkies ISJ, Scheltens-de Boer M, van Leusden JA, et al. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry. 2007;78(9):1012–3.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Xiao Y, Huang J, Luo H, Wang J. Mycophenolate mofetil for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2014;2:CD010242. Xiao Y, Huang J, Luo H, Wang J. Mycophenolate mofetil for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2014;2:CD010242.
35.
Zurück zum Zitat Bagherpour B, Salehi M, Jafari R, Bagheri A, Kiani-Esfahani A, Edalati M, et al. Promising effect of rapamycin on multiple sclerosis. Mult Scler Relat Disord. 2018;26:40–5.CrossRefPubMed Bagherpour B, Salehi M, Jafari R, Bagheri A, Kiani-Esfahani A, Edalati M, et al. Promising effect of rapamycin on multiple sclerosis. Mult Scler Relat Disord. 2018;26:40–5.CrossRefPubMed
36.
Zurück zum Zitat Besnard C, Levy E, Aladjidi N, Stolzenberg M-C, Magerus-Chatinet A, Alibeu O, et al. Pediatric-onset Evans syndrome: heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clin Immunol Orlando Fla. 2018;188:52–7.CrossRef Besnard C, Levy E, Aladjidi N, Stolzenberg M-C, Magerus-Chatinet A, Alibeu O, et al. Pediatric-onset Evans syndrome: heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clin Immunol Orlando Fla. 2018;188:52–7.CrossRef
37.
Zurück zum Zitat Brignier AC, Mahlaoui N, Reimann C, Picard C, Kracker S, de Vergnes N, et al. Early-onset hypogammaglobulinemia: a survey of 44 patients. J Allergy Clin Immunol. 2015;136(4):1097–1099.e2.CrossRefPubMed Brignier AC, Mahlaoui N, Reimann C, Picard C, Kracker S, de Vergnes N, et al. Early-onset hypogammaglobulinemia: a survey of 44 patients. J Allergy Clin Immunol. 2015;136(4):1097–1099.e2.CrossRefPubMed
38.
Zurück zum Zitat Tison BE, Nicholas SK, Abramson SL, Hanson IC, Paul ME, Seeborg FO, et al. Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome. J Allergy Clin Immunol. 2011;128(5):1115–1117.e3.CrossRefPubMed Tison BE, Nicholas SK, Abramson SL, Hanson IC, Paul ME, Seeborg FO, et al. Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome. J Allergy Clin Immunol. 2011;128(5):1115–1117.e3.CrossRefPubMed
39.
Zurück zum Zitat Colarusso G, Gambineri E, Lapi E, Casini T, Tucci F, Lippi F, et al. Evans syndrome and antibody deficiency: an atypical presentation of chromosome 22q11.2 deletion syndrome. Pediatr Rep. 2010;2(2):e13. Colarusso G, Gambineri E, Lapi E, Casini T, Tucci F, Lippi F, et al. Evans syndrome and antibody deficiency: an atypical presentation of chromosome 22q11.2 deletion syndrome. Pediatr Rep. 2010;2(2):e13.
40.
Zurück zum Zitat Kratz CP, Niehues T, Lyding S, Heusch A, Janssen G, Göbel U. Evans syndrome in a patient with chromosome 22q11.2 deletion syndrome: a case report. Pediatr Hematol Oncol. 2003;20(2):167–72.CrossRefPubMed Kratz CP, Niehues T, Lyding S, Heusch A, Janssen G, Göbel U. Evans syndrome in a patient with chromosome 22q11.2 deletion syndrome: a case report. Pediatr Hematol Oncol. 2003;20(2):167–72.CrossRefPubMed
41.
Zurück zum Zitat Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–7.CrossRefPubMedPubMedCentral Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–7.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–6.CrossRefPubMedPubMedCentral Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–6.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015 Jul 24;349(6246):436–40.CrossRefPubMed Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015 Jul 24;349(6246):436–40.CrossRefPubMed
44.
Zurück zum Zitat Lopez-Herrera G, Tampella G, Pan-Hammarström Q, Herholz P, Trujillo-Vargas CM, Phadwal K, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet. 2012;90(6):986–1001.CrossRefPubMedPubMedCentral Lopez-Herrera G, Tampella G, Pan-Hammarström Q, Herholz P, Trujillo-Vargas CM, Phadwal K, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet. 2012;90(6):986–1001.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Alangari A, Alsultan A, Adly N, Massaad MJ, Kiani IS, Aljebreen A, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol. 2012;130(2):481–488.e2.CrossRefPubMedPubMedCentral Alangari A, Alsultan A, Adly N, Massaad MJ, Kiani IS, Aljebreen A, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol. 2012;130(2):481–488.e2.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Burns SO, Zenner HL, Plagnol V, Curtis J, Mok K, Eisenhut M, et al. LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia. J Allergy Clin Immunol. 2012 Dec;130(6):1428–32.CrossRefPubMedPubMedCentral Burns SO, Zenner HL, Plagnol V, Curtis J, Mok K, Eisenhut M, et al. LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia. J Allergy Clin Immunol. 2012 Dec;130(6):1428–32.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Seidel MG, Hirschmugl T, Gamez-Diaz L, Schwinger W, Serwas N, Deutschmann A, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. J Allergy Clin Immunol. 2015;135(5):1384–1390.e1–8.CrossRefPubMedPubMedCentral Seidel MG, Hirschmugl T, Gamez-Diaz L, Schwinger W, Serwas N, Deutschmann A, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. J Allergy Clin Immunol. 2015;135(5):1384–1390.e1–8.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Charbonnier L-M, Janssen E, Chou J, Ohsumi TK, Keles S, Hsu JT, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol. 2015;135(1):217–27.CrossRefPubMed Charbonnier L-M, Janssen E, Chou J, Ohsumi TK, Keles S, Hsu JT, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol. 2015;135(1):217–27.CrossRefPubMed
49.
Zurück zum Zitat Hayakawa S, Okada S, Tsumura M, Sakata S, Ueno Y, Imai K, et al. A patient with CTLA-4 haploinsufficiency presenting gastric cancer. J Clin Immunol. 2016;36(1):28–32.CrossRefPubMed Hayakawa S, Okada S, Tsumura M, Sakata S, Ueno Y, Imai K, et al. A patient with CTLA-4 haploinsufficiency presenting gastric cancer. J Clin Immunol. 2016;36(1):28–32.CrossRefPubMed
50.
Zurück zum Zitat Gámez-Díaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 2016;137(1):223–30.CrossRefPubMed Gámez-Díaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 2016;137(1):223–30.CrossRefPubMed
51.
Zurück zum Zitat Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 CTLA-4-insufficient individuals. J Allergy Clin Immunol. 2018;142(6):1932–1946. Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 CTLA-4-insufficient individuals. J Allergy Clin Immunol. 2018;142(6):1932–1946.
52.
Zurück zum Zitat Notarangelo LD, Fleisher TA. Targeted strategies directed at the molecular defect: toward precision medicine for select primary immunodeficiency disorders. J Allergy Clin Immunol. 2017 Mar;139(3):715–23.CrossRefPubMedPubMedCentral Notarangelo LD, Fleisher TA. Targeted strategies directed at the molecular defect: toward precision medicine for select primary immunodeficiency disorders. J Allergy Clin Immunol. 2017 Mar;139(3):715–23.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Lee S, Moon JS, Lee C-R, Kim H-E, Baek S-M, Hwang S, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. 2016 Jan;137(1):327–30.CrossRefPubMed Lee S, Moon JS, Lee C-R, Kim H-E, Baek S-M, Hwang S, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. 2016 Jan;137(1):327–30.CrossRefPubMed
54.
Zurück zum Zitat van Leeuwen EM, Cuadrado E, Gerrits AM, Witteveen E, de Bree GJ. Treatment of intracerebral lesions with Abatacept in a CTLA4-Haploinsufficient patient. J Clin Immunol. 2018;38(4):464–467. van Leeuwen EM, Cuadrado E, Gerrits AM, Witteveen E, de Bree GJ. Treatment of intracerebral lesions with Abatacept in a CTLA4-Haploinsufficient patient. J Clin Immunol. 2018;38(4):464–467.
Metadaten
Titel
Neurological Involvement in Childhood Evans Syndrome
verfasst von
Thomas Pincez
Bénédicte Neven
Hubert Ducou Le Pointe
Pascale Varlet
Helder Fernandes
Albane Gareton
Guy Leverger
Thierry Leblanc
Hervé Chambost
Gérard Michel
Marlène Pasquet
Frédéric Millot
Olivier Hermine
Alexis Mathian
Marie Hully
Hélène Zephir
Mohamed Hamidou
Jean-Marc Durand
Yves Perel
Judith Landman-Parker
Fréderic Rieux-Laucat
Nathalie Aladjidi
Publikationsdatum
22.01.2019
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 2/2019
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-019-0594-3

Weitere Artikel der Ausgabe 2/2019

Journal of Clinical Immunology 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.